CG
NVO

Cynosure Group’s Novo Nordisk NVO Stock Holding History

Cynosure Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,094
Closed -$283K – 492
2025
Q3 		$283K Hold
5,094
– – 0.03% 351
2025
Q2 		$352K Sell
5,094
-4,710
-48% -$320K 0.04% 345
2025
Q1 		$681K Sell
9,804
-16,906
-63% -$1.4M 0.09% 114
2024
Q4 		$2.3M Buy
26,710
+19,003
+247% +$2.05M 0.34% 39
2024
Q3 		$918K Sell
7,707
-214
-3% -$28.5K 0.13% 77
2024
Q2 		$1.13M Buy
7,921
+496
+7% +$65.7K 0.18% 74
2024
Q1 		$953K Buy
7,425
+624
+9% +$74.3K 0.17% 68
2023
Q4 		$704K Buy
6,801
+248
+4% +$24.5K 0.13% 108
2023
Q3 		$596K Buy
+6,553
New +$577K 0.18% 104

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cynosure Group's NVO Position: Q4 2025 in Review

Cynosure Group sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 5,094 shares — an estimated $283K sold.

Cynosure Group first reported a position in NVO in Q3 2023 and held it in 9 quarters. The position peaked at $2.3M in Q4 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Cynosure Group reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Cynosure Group sold 5,094 Novo Nordisk shares in Q4 2025, an estimated $283K.
  • Cynosure Group first reported a position in Novo Nordisk in Q3 2023 and held it in 9 quarters.
  • Cynosure Group's Novo Nordisk position peaked at $2.3M in Q4 2024.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Cynosure Group's 13F filing for Q4 2025, filed 17 Feb 2026.